IL-1F9 CRISPR/Cas9 KO Plasmid (h): sc-406176
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IL-1F9 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the IL-1F9 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IL-1F9 Antibody (Y-12): sc-80056
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IL-1F9 CRISPR/Cas9 KO Plasmid (h) | sc-406176 | 20 µg | $397.00 |
Overview
IL36G encodes interleukin-36 gamma (IL-1F9), an IL-1 family cytokine that acts as an epithelial- and myeloid-derived alarmin to amplify innate and adaptive immune responses. Upon proteolytic activation, IL-1F9 signals through the IL-36 receptor complex (IL1RL2/IL1RAP) to trigger NF-κB and MAPK pathways, driving expression of chemokines and inflammatory mediators that recruit and activate leukocytes. This axis contributes to barrier immunity at skin and mucosal surfaces and shapes Th17-associated inflammation through crosstalk with IL-17/IL-23 programs. Dysregulated IL36G activity has been implicated in inflammatory skin disorders such as psoriasis and in broader contexts of chronic tissue inflammation, making it a useful node for studying cytokine-network amplification and epithelial immune signaling.
IL-1F9 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the IL36G gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the IL36G together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the IL36G open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish IL-1F9 protein expression.
This CRISPR knockout system enables efficient generation of IL36G-deficient cell models for investigation of IL-1F9 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting IL36G exon(s) critical for IL-1F9 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple IL36G genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by IL-1F9 CRISPR/Cas9 KO Plasmid (h) and IL-1F9 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the IL36G locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by IL-1F9 HDR Plasmid (h) and IL-1F9 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by IL36G homology arms to support homology-directed repair at defined IL36G target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.